11–16 May 2014
Casino Conference Centre
Europe/Prague timezone

Session

Plenary session 2

PLE-2
12 May 2014, 10:30
Casino Conference Centre

Casino Conference Centre

Reitenbergerova 4/95, Mari&#225;nsk&#233; L&#225;zn&#283;, Czech Republic <font color=white>

Conveners

Plenary session 2

  • Andreas Türler (Paul Scherrer Institute and Bern University)
  • Michio Aoyama (Institute of Environmental Radioactivity, Fukushima University)

Presentation materials

There are no materials yet.

  1. Prof. Bert Wolterbeek (Delft University of Technology)
    12/05/2014, 10:30
    Production and Application of Radionuclides
    Plenary
    The present paper addresses eight possible routes of producing 99Mo, and discusses both yield and 99Mo specific activities (SA) in the context of future anticipated worldwide demand. The dimensions of the targets are modelled by considering both the limits set by cooling and those by inside-target radiation attenuation characteristics. Energy deposition profiles are modelled by MCNP6, the...
    Go to contribution page
  2. Dr Stéphane Bourg (CEA, Nuclear Energy Division, RadioChemistry & Processes Department)
    12/05/2014, 11:00
    Chemistry of Nuclear Fuel Cycle / 1st ASGARD International Workshop
    Plenary
    Actinide chemistry is at the centre of key issues to be faced by nuclear energy. Indeed, in addition to an increased safety of the reactors themselves, the acceptance of the nuclear energy is still closely associated to our capability to reduce the lifetime of the nuclear waste, to manage them safely in a long term disposal and to propose options for a better use of the natural resources....
    Go to contribution page
  3. Dr Emma Aneheim (Sahlgrenska Academy at Gothenburg University)
    12/05/2014, 11:30
    Radiopharmaceutical Chemistry, Labelled Compounds
    Plenary
    One of the greatest challenges in the treatment of different types of cancers is an efficient therapy of occult metastasis. Today chemotherapy is generally employed as an adjuvant treatment to eradicate the minimal residual disease. However, despite that chemotherapy often is a very aggressive method the cancer cells can transform and become resistant towards the chemicals used. This means...
    Go to contribution page
Building timetable...